Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A
2015-002378-19Phase 3Completed
- Sponsor
- Pharnext
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of PXT 3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) and Charcot-Marie-Tooth disease (CMT) (3 arms), sponsored by Pharnext. Primary endpoint: Overall Neuropathy Limitation Scale (ONLS) score. Started Jul 2015; status: completed.
02
Drugs
PXT 3003
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)Charcot-Marie-Tooth disease (CMT)
Beyond the preview
Go deeper on 2015-002378-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002378-19.